Sales & Earnings In Brief
Herbalife's "soft" spot: Multilevel nutritional supplement marketer Herbalife reaches record annual net sales of $2.4 billion for 2008 despite an 11.3 percent drop in fourth-quarter net sales to $512.9 million. "Unprecedented currency fluctuations" cut into fourth-quarter income, reducing net sales by 856 basis points and causing a 2.7 percent drop in local currency year-over-year sales, the Los Angeles-based company says Feb. 24. "We ended the year on a soft note," Chairman and CEO Michael Johnson said. The company in December began restructuring to lower costs by improving alignment with its distributors and reducing workload. For the October-December period, the company's net income fell 59.6 percent to $33.7 million, due in part to general and administration expenses and lower sales. Fourth-quarter sales were down in each of the firm's regions other than a flat performance in North America, $109.3 million. Sales dropped 18.9 percent in Europe, the Middle East and Africa region to $117.4 million, 4.5 percent in Asia Pacific to $97 million, 20.7 percent in South America to $78.8 million and 28.5 percent in Mexico and Central America to $69.9 million, Herbalife said. Full-year sales grew 9.9 percent and net income grew 13.4 percent to $221.2 million, or $3.36 per diluted share. Herbalife added 45,657 sales associates in the quarter, 19.5 percent fewer than the year-ago period, but the number increased 6.6 percent for the year to 505,094
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
The preliminary White House 2026 budget plan cuts agency funding, but not so sharply that user fees are excluded from collection.
An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include four new products, one of which is Tivdak, Pfizer/Genmab’s treatment for previously treated recurrent or metastatic cervical cancer.